Bill Emmott, former Editor-in-Chief at The Economist, joins Airfinity’s advisory board as the company expands its global public health data offering. 

Bill Emmott by John Cairns 28.4.17-028

Former Editor of The Economist joins Airfinity as advisor 

China updated forecast

China updated forecast 2

tran-huy-f6H2Epsn63w-unsplash

China to see one longer, more severe COVID wave as Lunar Festival fuels outbreak

Our CEO Rasmus Bech Hansen spoke to Bloomberg’s Guy Johnson and Alix Steel about what cuts to testing and restrictions ending could really mean as COVID surges across China.

Screenshot 2022-12-13 at 13.57.16

Airfinity CEO Says Covid Peak Could Go Much Higher

kate-trifo-6Ps0pMoln A-unsplash

China’s ‘zero-COVID’ limits saved lives but no clear exit

mat-napo-At-LUvX6Eto-unsplash

Without a nasal vaccine, the U.S. edge in fighting Covid is on the line

Biorisk

Airfinity launches the world’s most comprehensive infectious disease surveillance solution.

rinke-dohmen-1aUaNgk56LE-unsplash

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

AZ RSV Drug 

Airfinity analysis shows Astrazeneca's monoclonal infant RSV drug could be administered to up to 3.5 million infants under one year of age in Europe once approved which would generate a potential revenue of up to $1.1bn. 

cdc-fx9RJgZYRUE-unsplash

AstraZeneca’s infant RSV drug Beyfortus could generate $1.1bn sales revenue

Airfinity analysis shows the potential global demand for the monkeypox vaccine under three potential demand scenarios. 

syringes-g3418b9fd4 1920

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Analysis by Airfinity shows the AstraZeneca and Pfizer/BioNTech vaccines saved the most lives in the first year of the global vaccination campaign.

Newsroom

Featured